Download Slides - View the full AIDS 2016 programme

Rapidly falling costs for new
hepatitis C direct-acting antivirals:
potential for universal access
Dzintars Gotham1, Melissa Barber2, Joseph Fortunak3, Anton Pozniak4, Andrew Hill4
1
Faculty of Medicine, Imperial College London, London, United Kingdom.
2 Centre of Development Studies, Cambridge University, Cambridge, United Kingdom.
3 Chemistry and Pharmaceutical Sciences, Howard University, Washington, DC, USA.
4 St Stephens AIDS Trust, Chelsea and Westminster Hospital, London, UK.
Correspondence to:
Dr Andrew Hill
[email protected]
Abstract THPDE0206
Cost/kg of sofosbuvir API exports Jan to Jun 2016,
weighted by size of shipment
Gotham D, Barber M, Fortunak J, Pozniak A, Hill A. Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): potential for universal access.
Abstract number A-792-0516-01639, presented at AIDS2016, Durban.
Cost-based generic price of sofosbuvir (12 weeks)
Cost of API =
$1,094/kg
API needed per person = 34g (400mg x 84 days)
API per 12 weeks
= $37
Formulation + excipients = $0.04 per pill
Formulated drug
= $40
Packaging = $0.35/month
Packaged drug
= $41
Profit margin = 50%
Final generic price
= $62
Gotham D, Barber M, Fortunak J, Pozniak A, Hill A. Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): potential for universal access.
Abstract number A-792-0516-01639, presented at AIDS2016, Durban.
Costs of API, calculated target prices, and current prices
Drug
API cost/kg
Target price for
finished product
per treatment
Sofosbuvir (SOF)
$1,094
$62
Daclatasvir
$998
$14
Ledipasvir (LDV)
$2,441
$34
SOF+LDV
N/A
$96
Velpatasvir (VEL)
$8,900-11,700
$119-154
SOF+VEL
N/A
$181-216
Gotham D, Barber M, Fortunak J, Pozniak A, Hill A. Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): potential for universal access.
Abstract number A-792-0516-01639, presented at AIDS2016, Durban.
Gotham D, Barber M, Fortunak J, Pozniak A, Hill A. Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): potential for universal access.
Abstract number A-792-0516-01639, presented at AIDS2016, Durban.
Target $ 62
India $ 324
$ 6,875
Brazil
$ 44,689
Canada
$ 27,634
$ 45,323
Germany
Portugal
$ 45,323
France
$ 27,634
$ 50,300
UK
Spain
$ 49,860
US (Vet. Affairs)
$ 84,000
$ 90,000
$ 75,000
$ 60,000
$ 45,000
$ 30,000
$ 15,000
$0
US (list price)
price for 12-week treatment course
Lowest prices of sofosbuvir in selected countries
$ 35,174
Spain
$ 2,552
$15,000
Brazil
US (Veterans
Affairs)
$0
Gotham D, Barber M, Fortunak J, Pozniak A, Hill A. Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): potential for universal access.
Abstract number A-792-0516-01639, presented at AIDS2016, Durban.
Target $ 14
$ 37,152
UK
$30,000
India $ 153
$ 39,387
$45,000
France
$60,000
$ 50,653
$ 63,000
$75,000
US (list price)
price for 12-week treatment course
Lowest prices of daclatasvir in selected countries
Estimated generic price, including a
50% profit margin, for 12 weeks of
treatment:
SOF: $62
SOF+DCV: $76
SOF+LDV: $96
SOF+VEL: $181-$216